Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 plus AG ± SHR-1316 in KRAS G12D-mutated advanced pancreatic cancer
ChiCTR2500115250Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of HRS-4642 in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-free survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
HRS-4642
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2500115250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115250.